AssetMark Inc
BMY icon

AssetMark Inc’s Bristol-Myers Squibb BMY Stock Holding History

AssetMark Inc’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.78M Sell
144,837
-24,825
-15% -$1.45M 0.02% 534
2025
Q4 		$9.15M Sell
169,662
-70,960
-29% -$3.41M 0.02% 517
2025
Q3 		$10.9M Buy
240,622
+34,057
+16% +$1.59M 0.02% 438
2025
Q2 		$9.56M Sell
206,565
-57,008
-22% -$2.8M 0.02% 413
2025
Q1 		$16.1M Buy
263,573
+3,952
+2% +$230K 0.04% 288
2024
Q4 		$14.7M Buy
259,621
+60,954
+31% +$3.41M 0.04% 298
2024
Q3 		$10.3M Buy
198,667
+26,408
+15% +$1.24M 0.03% 324
2024
Q2 		$7.15M Sell
172,259
-18,195
-10% -$814K 0.02% 365
2024
Q1 		$10.3M Buy
190,454
+34,770
+22% +$1.77M 0.03% 294
2023
Q4 		$7.99M Buy
155,684
+15,329
+11% +$805K 0.03% 302
2023
Q3 		$8.15M Buy
140,355
+12,846
+10% +$787K 0.03% 272
2023
Q2 		$8.15M Buy
127,509
+15,722
+14% +$1.05M 0.03% 274
2023
Q1 		$7.75M Buy
111,787
+26,270
+31% +$1.85M 0.03% 270
2022
Q4 		$6.15M Buy
85,517
+15,198
+22% +$1.15M 0.03% 273
2022
Q3 		$5M Buy
70,319
+24,352
+53% +$1.77M 0.02% 270
2022
Q2 		$3.54M Buy
45,967
+16,085
+54% +$1.23M 0.02% 287
2022
Q1 		$2.18M Buy
29,882
+9,006
+43% +$605K 0.01% 333
2021
Q4 		$1.3M Buy
20,876
+1,052
+5% +$61.7K 0.01% 375
2021
Q3 		$1.17M Sell
19,824
-1,196
-6% -$78.8K 0.01% 380
2021
Q2 		$1.41M Buy
21,020
+69
+0.3% +$4.5K 0.01% 356
2021
Q1 		$1.32M Sell
20,951
-11,008
-34% -$685K 0.01% 340
2020
Q4 		$1.98M Sell
31,959
-461,763
-94% -$28.4M 0.01% 301
2020
Q3 		$29.8M Buy
493,722
+154,295
+45% +$9.29M 0.19% 119
2020
Q2 		$19.6M Buy
339,427
+82,876
+32% +$4.96M 0.14% 140
2020
Q1 		$14.3M Sell
256,551
-214,815
-46% -$13.1M 0.12% 148
2019
Q4 		$30.3M Buy
471,366
+237,860
+102% +$13.6M 0.23% 109
2019
Q3 		$11.8M Buy
233,506
+230,553
+7,807% +$10.8M 0.1% 183
2019
Q2 		$134K Buy
2,953
+107
+4% +$4.98K ﹤0.01% 543
2019
Q1 		$136K Buy
2,846
+333
+13% +$16.6K ﹤0.01% 514
2018
Q4 		$131K Sell
2,513
-1,127
-31% -$60.6K ﹤0.01% 508
2018
Q3 		$226K Sell
3,640
-581
-14% -$34.5K ﹤0.01% 439
2018
Q2 		$234K Buy
4,221
+487
+13% +$26.3K ﹤0.01% 432
2018
Q1 		$236K Sell
3,734
-2,345
-39% -$151K ﹤0.01% 425
2017
Q4 		$373K Buy
6,079
+1,394
+30% +$87.2K ﹤0.01% 401
2017
Q3 		$299K Sell
4,685
-650,705
-99% -$38M ﹤0.01% 418
2017
Q2 		$36.5M Buy
655,390
+55,062
+9% +$3M 0.46% 64
2017
Q1 		$32.6M Buy
600,328
+97,374
+19% +$5.34M 0.43% 65
2016
Q4 		$29.4M Buy
502,954
+47,845
+11% +$2.62M 0.43% 64
2016
Q3 		$24.5M Buy
455,109
+452,171
+15,390% +$29M 0.37% 69
2016
Q2 		$216K Sell
2,938
-283
-9% -$20K ﹤0.01% 389
2016
Q1 		$206K Buy
3,221
+349
+12% +$22K ﹤0.01% 366
2015
Q4 		$198K Buy
2,872
+2,720
+1,789% +$180K ﹤0.01% 435
2015
Q3 		$9K Sell
152
-207
-58% -$13.1K ﹤0.01% 492
2015
Q2 		$24K Buy
+359
New +$23.7K ﹤0.01% 451

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AssetMark Inc's BMY Position: Q1 2026 in Review

AssetMark Inc reduced its Bristol-Myers Squibb (BMY) stake by 15% in Q1 2026, selling an estimated $1.45M and leaving 144,837 shares worth $8.78M. The position accounts for 0.02% of the portfolio, ranked #534.

AssetMark Inc first reported a position in BMY in Q2 2015 and has held it in 44 quarters since. The position peaked at $36.5M in Q2 2017. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • AssetMark Inc held 144,837 shares of Bristol-Myers Squibb worth $8.78M as of Q1 2026.
  • AssetMark Inc sold 24,825 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.45M.
  • Bristol-Myers Squibb made up 0.02% of AssetMark Inc's portfolio in Q1 2026, its #534 holding.
  • AssetMark Inc first reported a position in Bristol-Myers Squibb in Q2 2015 and has held it in 44 quarters since.
  • AssetMark Inc's Bristol-Myers Squibb position peaked at $36.5M in Q2 2017.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.